- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Kite Pharma Reports Positive Data From ZUMA-1, Evaluating a CAR-T Treatment
Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.
Kite Pharma, a pioneer in developing the chimeric antigen receptor (CAR)-T cell treatment, has announced that median overall survival (OS) was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.
The trial, being conducted in patients with chemotherapy-resistant aggressive B-cell non-Hodgkin lymphoma (NHL), is testing axicabtagene ciloleucel (previously referred to as KTE-C19). Interim analysis of the data showed that the trial met its primary endpoints of objective response rate (ORR), complete response (CR), and partial response (PR), following a single infusion of axicabtagene ciloleucel.
Of the 101 trial participants, 41% achieved ORR at 6 months (P <.0001), 36% had a CR, and 5% of patients had a durable PR. One of the partial responders became a complete responder at 9 months following infusion. More importantly, the trial was yet to reach a median OS at nearly 9 months of follow-up.
The following grade 3 or higher adverse events were reported from the trial:
- Anemia (43%)
- Neutropenia (39%)
- Decreased neutrophil count (32%)
- Febrile neutropenia (31%)
- Decreased white blood cell count (29%)
- Thrombocytopenia (24%)
- Encephalopathy (21%)
- Decreased lymphocyte count (20%)
No cases of cerebral edema were reported, unlike the JCAR015 trial. Grade 3 or higher cytokine release syndrome, very commonly observed with CAR-T treatment, decreased from 18% to 13%.
“Several patients we treated at Moffitt Cancer Center experienced a rapid and durable complete response with this first-of-its kind therapy,” Frederick L. Locke, MD, ZUMA-1 co-lead investigator, and director of research for the Immune Cell Therapy Program at Moffitt Cancer Center, said in a statement. "The ZUMA-1 study results suggest that axicabtagene ciloleucel could become a new standard of care for patients with refractory aggressive lymphoma."
The company is planning to submit a rolling Biologics License Application based on these results by the end of the first quarter of 2017.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Study Finds Obesity May Worsen Multiple Sclerosis: Genetic Analysis Points to Causal Link
November 21st 2024A new study aimed at exploring the relationship between obesity and multiple sclerosis severity using genetic data finds that higher BMI and other obesity measures were associated with increased disability progression in patients with MS.
Read More
